An appraisal of emerging second line therapies for metastatic colorectal cancer.
Cristina SmolenschiAudrey PerretFrançois Dall'ArmellinaValerie BoigeDavid MalkaAntoine HollebecqueMichel DucreuxPublished in: Expert review of gastroenterology & hepatology (2020)
Some choices of second-line treatments are a direct result of the option chosen in the first line. Others are necessary because of the biological specificity of the tumor: immunotherapy for tumors with microsatellite instability, or the combination encorafenib cetuximab for mutated BRAF-V600E tumors. In many other circumstances, there are several options that require extensive involvement of multidisciplinary boards and the patient in the final therapeutic decision.